This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Depomed Announces Appointment Of Louis J. Lavigne, Jr. To Board Of Directors

NEWARK, Calif., July 8, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of Louis J. Lavigne, Jr. to the company's Board of Directors, and to the Board's Audit Committee.  Mr. Lavigne is the former Executive Vice President and Chief Financial Officer of Genentech.

"Lou is a highly skilled life sciences veteran with experience leading companies through extraordinary growth.  His insight and breadth of expertise in strategy, finance and operations will be invaluable to Depomed as we continue to build the company and our specialty pharmaceutical business," said James Schoeneck, Depomed's President and CEO. 

"I am excited to join Depomed's Board of Directors in the next key phase of the company's development and look forward to making a contribution to Depomed's growth," said Mr. Lavigne.

Mr. Lavigne is currently Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth strategy and management.  He was Executive Vice President and Chief Financial Officer of Genentech, Inc. from 1997 through his retirement in 2005.  He joined Genentech in 1982 and assumed the position of Chief Financial Officer in 1988.  Mr. Lavigne currently serves on the boards of Allergan, Inc., BMC Software, Inc., Accuray Incorporated, Novocure Limited and SafeNet Inc.  He is a member of Deloitte's Life Sciences Advisory Board.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products.  Gralise ® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.  Glumetza ® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States.  The company formulates its products and product candidates with its proven, proprietary Acuform ® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the company's anticipated future growth, and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2012 and its most recently Quarterly Report on Form 10-Q.  The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT: August J. MorettiDepomed, Inc.510.744.8000 amoretti@depomed.com

SOURCE Depomed

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.57 -9.57 -0.05%
S&P 500 2,111.93 -5.76 -0.27%
NASDAQ 5,060.8070 -31.2780 -0.61%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs